News
Media
Conferences
Partners
Publications
Events
CME/CE
Resources
PBM Directory
Subscribe

Spotlight -

MHE State of the Industry survey|

AMCP Nexus 2025|

2025 Fall Clinical Dermatology|

Opinion|Videos|August 1, 2024

Managing Acute Exacerbations and the Psychosocial Aspect of Idiopathic and Progressive Pulmonary Fibrosis

Author(s)Paul Frohna, MD, PhD

An expert pulmonologist discusses the best ways to manage acute exacerbations and the psychosocial component of idiopathic and progressive pulmonary fibrosis.

Episodes in this series

EP. 1 Symptoms, Manifestations and Mortality Rate of IPF

EP. 1 Symptoms, Manifestations and Mortality Rate of IPF

EP. 2 How the GAP Program Helps Determine Patient Prognosis, and Risk Factors for Developing IPF/PPF

EP. 2 How the GAP Program Helps Determine Patient Prognosis, and Risk Factors for Developing IPF/PPF

EP. 3 Epidemiology Facts, Differential Diagnosis, and Arriving at a IPF or PPF Diagnosis

EP. 3 Epidemiology Facts, Differential Diagnosis, and Arriving at a IPF or PPF Diagnosis

EP. 4 Critical Early Diagnoses and Acute Exacerbations in IPF and PPF

EP. 4 Critical Early Diagnoses and Acute Exacerbations in IPF and PPF

1 KOL is featured in this series.

EP. 5 Exploring the Role of Non-Pharmacological Modalities and Multidisciplinary Care in Patients with Idiopathic and Progressive Pulmonary Fibrosis

1 KOL is featured in this series.

EP. 6 Managing Acute Exacerbations and the Psychosocial Aspect of Idiopathic and Progressive Pulmonary Fibrosis

1 KOL is featured in this series.

EP. 7 Key Unmet Needs Associated with Idiopathic and Progressive Pulmonary Fibrosis

EP. 8 The Roles of Biomarker Testing and HRCT in IPF and PPF

EP. 8 The Roles of Biomarker Testing and HRCT in IPF and PPF

EP. 9 Unmet Needs and the Role of AI in Earlier Disease Detection

EP. 9 Unmet Needs and the Role of AI in Earlier Disease Detection

1 KOL is featured in this series.

EP. 10 Adverse Events Associated with Anti-Fibrotic Therapies

1 KOL is featured in this series.

EP. 11 Investigational Agents for Idiopathic and Progressive Pulmonary Fibrosis

1 KOL is featured in this series.

EP. 12 The Future of Idiopathic and Progressive Pulmonary Fibrosis Treatment

EP. 13 K-Cast Written Summary. Exploring Key Unmet Needs in Idiopathic Pulmonary Fibrosis

EP. 13 K-Cast Written Summary. Exploring Key Unmet Needs in Idiopathic Pulmonary Fibrosis

How are acute exacerbations of IPF/PPF managed, and what is the role of corticosteroids?
What are the key pearls to managing the psychosocial aspects of this disease, such as depression, anxiety, and sleep disturbance?

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Related Content

man applying hand cream | Image credit: Africa Studio - stock.adobe.com

Top 5 most-read stories out of the 2025 AAD annual meeting

ByLaura Joszt, MA

December 17th 2025

2 experts are featured in this series

Limitations of Current Evidence for BRAF V600E-Mutant Metastatic NSCLC and Cross-Trial Comparisons

ByJulia Rotow, MD ,Ibiayi Dagogo-Jack, MD

December 15th 2025

2 experts are featured in this series

CNS Disease Considerations and Implications for Treatment Selection for BRAF V600E-Mutant Metastatic NSCLC

ByJulia Rotow, MD ,Ibiayi Dagogo-Jack, MD

December 15th 2025

2 experts are featured in this series

Practical Monitoring Strategies and Early Treatment Assessments in Patients with BRAF V600E-Mutant Metastatic NSCLC

ByJulia Rotow, MD ,Ibiayi Dagogo-Jack, MD

December 8th 2025

2 experts are featured in this series

Safety Profile of Encorafenib + Binimetinib and Management of Key Toxicities When Treating Patients with BRAF V600E-Mutant Metastatic NSCLC

ByJulia Rotow, MD ,Ibiayi Dagogo-Jack, MD

December 8th 2025

Latest CME

Burst CME™: Exploring Diagnosis and Testing Innovations for Targetable Mutations in SCLC

Burst CME™: Exploring Diagnosis and Testing Innovations for Targetable Mutations in SCLC

Jacob Sands, MD; Carl M. Gay, MD, PhD

Burst CME™: Addressing Diagnostic Challenges and Identifying Targets for Treatment in LCNEC-L

Burst CME™: Addressing Diagnostic Challenges and Identifying Targets for Treatment in LCNEC-L

Jacob Sands, MD; Martin Wermke, MD

Burst CME™: Advanced Diagnostic and Testing Approaches for Mutation-Targetable Management of NSCLC

Burst CME™: Advanced Diagnostic and Testing Approaches for Mutation-Targetable Management of NSCLC

Jacob Sands, MD; Julia Rotow, MD

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Missouri

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Missouri

Erminia Massarelli, MD, PhD, MS; Rashad Khan, MD

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | New Mexico

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | New Mexico

Erminia Massarelli, MD, PhD, MS; Sandhya Sharma, MD

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | North Carolina

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | North Carolina

Jacob Sands, MD; Venu Madhav Konala, MD, FACP

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | West Virginia

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | West Virginia

Zofia Piotrowska, MD, MHS; Alejandro R. Calvo, MD, FACP

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Tennessee

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Tennessee

Zofia Piotrowska, MD, MHS; Swati Vishwanathan, MD

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Washington

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Washington

Zofia Piotrowska, MD, MHS; Robert Hsu, MD

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Texas

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Texas

Millie Das, MD; Rebecca Yarborough, MD

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Arkansas

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Arkansas

Charu Aggarwal, MD, MPH, FASCO; Philip A. Haddad, MD, MPH, MHA, MS(HCI)

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kentucky

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kentucky

Charu Aggarwal, MD, MPH, FASCO; Jack W. Erter III, MD, MMHC

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | New York

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | New York

Anne Chiang, MD, PhD; Adriana L. Alvarez, MD

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Iowa

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Iowa

Anne Chiang, MD, PhD; Benjamin Scheier, MD

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Minnesota

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Minnesota

Erminia Massarelli, MD, PhD, MS; Frantz Francisque, MD

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

In-Person Event

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

January 22, 2026

23rd Annual Winter Lung Cancer Conference®

In-Person Event

23rd Annual Winter Lung Cancer Conference®

January 23-25, 2026

2nd Annual Hawaii Cancer Conference

In-Person Event

2nd Annual Hawaii Cancer Conference

January 24-25, 2026

Burst CME™: The Role of HER2 in NSCLC and Implications for Emerging Treatment Strategies

Burst CME™: The Role of HER2 in NSCLC and Implications for Emerging Treatment Strategies

Jacob Sands, MD; Julia Rotow, MD

Community Practice Connections™: 19th Annual New York Lung Cancers Symposium®

Community Practice Connections™: 19th Annual New York Lung Cancers Symposium®

Balazs Halmos, MD, MS; Mark G. Kris, MD; Jamie E. Chaft, MD; Zofia Piotrowska, MD, MHS

Future Directions in Treating SCLC and LCNEC-L: The Impact of DLL3

Future Directions in Treating SCLC and LCNEC-L: The Impact of DLL3

Jacob Sands, MD; Carl M. Gay, MD, PhD

42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow

42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow

Benjamin P. Levy, MD; John O. Mascarenhas, MD; Tiffany A. Traina, MD, FASCO; Cathy Eng, MD, FACP, FASCO; John P. Leonard, MD

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Community Practice Connections™: Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC

Community Practice Connections™: Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC

Zofia Piotrowska, MD, MHS; Bruna Pellini, MD; Alice Shaw, MD, PhD

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Stephen V. Liu, MD; Michelle Afkhami, MD; Ignacio I. Wistuba, MD; Helena Yu, MD

Mastering Advances in Managing Unresectable and Metastatic NSCLC—Immunotherapy, Targeted Therapies, and Emerging Strategies

Mastering Advances in Managing Unresectable and Metastatic NSCLC—Immunotherapy, Targeted Therapies, and Emerging Strategies

Marina Chiara Garassino, MD; Sarah Goldberg, MD, MPH; Biagio Ricciuti, MD, PhD

Cases & Conversations™: Expert Perspectives on Leveraging Recent Advances to Transform SCLC Treatment

Cases & Conversations™: Expert Perspectives on Leveraging Recent Advances to Transform SCLC Treatment

Jacob Sands, MD; Anne Chiang, MD, PhD; Alissa J. Cooper, MD

22nd Annual Winter Lung Cancer Conference®

22nd Annual Winter Lung Cancer Conference®

Julie Brahmer, MD; Rogerio C. Lilenbaum, MD, FACP, FASCO; Mark A. Socinski, MD

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Fred Hirsch, MD, PhD, FASCO; Andy Guinigundo, MSN, RN, CNP, ANP-BC, FAPO

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Fred Hirsch, MD, PhD, FASCO; Andy Guinigundo, MSN, RN, CNP, ANP-BC, FAPO

(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice

(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice

Lauren Averett Byers, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Benjamin P. Levy, MD; Ticiana Leal, MD; Aaron Lisberg, MD; Christine M. Lovly, MD, PhD, FASCO

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Medical Crossfire®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?

Medical Crossfire®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?

Jacob Sands, MD; Jennifer Carlisle, MD; Hossein Borghaei, DO, MS

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

27th Annual International Lung Cancer Congress®

In-Person Event

27th Annual International Lung Cancer Congress®

July 24-25, 2026

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MS

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhD

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhD

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Jonathan Goldman, MD; Erminia Massarelli, MD, PhD, MS; Jorge J. Nieva, MD; Ignacio I. Wistuba, MD

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Sandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHS

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Tina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhD

26th Annual International Lung Cancer Congress

26th Annual International Lung Cancer Congress

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FASCO

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

21st Annual New York Lung Cancers Symposium®

In-Person Event

21st Annual New York Lung Cancers Symposium®

November 14, 2026

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Charu Aggarwal, MD, MPH, FASCO; Zofia Piotrowska, MD, MHS

9th Annual School of Nursing Oncology™

9th Annual School of Nursing Oncology™

Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO; Beth Sandy, MSN, CRNP, FAPO; Lindsay Adkins, MSN, FNP-BC, BMTCN; Jeneth Aquino, DNP, FNP-BC; Casey Gormley, MSN, FNP-C, AOCNP; Heather J. Jackson, PhD, FNP-BC; Kelsey Martin, AG-ACNP-BC, AOCNP; Nerina T. McDonald, PA-C; Lauren Verity Moore, DNP, MSN, AGACNP-BC; Faith A. Mutale, DNP, CRNP; Tiffany Richards, PhD, ANP-BC, AOCNP; Emily Skotte, DNP, MSN, ACNP-BC; Leslie Smith, DNP, RN, APRN-CNS, AOCNS, BMTCN; Saneese Stephen, PA-C, MPAS; Sara M. Tinsley-Vance, PhD, APRN, AOCN

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Jacob Sands, MD; Anne Chiang, MD, PhD

20th Annual New York Lung Cancers Symposium®

20th Annual New York Lung Cancers Symposium®

Balazs Halmos, MD, MS; Jamie Chaft, MD

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Charles M. Rudin, MD, PhD; Anne Chiang, MD, PhD, FASCO; Jacob M. Sands, MD

3rd Annual Hawaii Lung: A Multidisciplinary Case-Based Conference

3rd Annual Hawaii Lung: A Multidisciplinary Case-Based Conference

David R. Gandara, MD; Roy S. Herbst, MD, PhD; Heather A. Wakelee, MD, FASCO

(Pharmacist Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(Pharmacist Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

Trending on Managed Healthcare Executive

Johns Hopkins experts warn of potentially severe flu season, measles elimination status faces risk

Many PCPs unaware of current ACIP shingles vaccine guidance, study finds

Will the end of enhanced ACA subsidies mean the beginning of a health insurance crisis?

Atopic dermatitis care advances in 2025 with new biologics, topicals and oral therapies

Kyverna to submit BLA for investigational CAR-T therapy for stiff-person syndrome